SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients.
暂无分享,去创建一个
O. Altundag | E. Gunduz | Y. Silay | K. Demircan | K. Altundağ | A. Mohamed
[1] F. Esteva. Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. , 2004, The oncologist.
[2] K. O'Byrne,et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] S. Franco,et al. Clinical Experience with Trastuzumab (Herceptin) , 2003, The breast journal.
[4] A. Dalgleish,et al. A randomized phase II trial of SRL172 (Mycobacterium vaccae) ± low-dose interleukin-2 in the treatment of metastatic malignant melanoma , 2003, Melanoma research.
[5] D. Yee,et al. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] C. Arteaga,et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.
[7] A. Padhani,et al. Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma , 2002, British Journal of Cancer.
[8] L. Assersohn,et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).
[9] D. Slamon,et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. , 2000, Seminars in oncology.
[10] C. Ryan,et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma , 2000, British Journal of Cancer.
[11] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[12] Jeffrey S. Miller,et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. , 1999, Experimental hematology.
[13] M. Sliwkowski,et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.
[14] B. Baban,et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Sliwkowski,et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.
[16] M. Groves,et al. Formulation and Biological Activity of Antineoplastic Proteoglycans Derived from Mycobacterium vaccae in Chitosan Nanoparticles , 1999, The Journal of pharmacy and pharmacology.
[17] B. Baban,et al. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). , 1998, British journal of urology.
[18] G. Rook,et al. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae , 1998, Immunology.
[19] N. Goldstein,et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.
[20] J. Watson,et al. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis , 1997, Infection and immunity.
[21] Yosef Yarden,et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.
[22] M. Clerici,et al. The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. , 1996, Journal of the National Cancer Institute.
[23] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[24] G. Rook,et al. Tuberculosis and cancer: parallels in host responses and therapeutic approaches? , 1995, The Lancet.
[25] T. Yamamoto,et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.
[26] P. Seeburg,et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.